Cargando…
Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group
The plasma concentration profile of bleomycin in the distribution phase of patients younger than 65 years is needed to determine the suitable time interval for efficient application of electric pulses during electrochemotherapy. Additionally, bleomycin concentrations in the treated tumors for effect...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469090/ https://www.ncbi.nlm.nih.gov/pubmed/34575400 http://dx.doi.org/10.3390/pharmaceutics13091324 |
_version_ | 1784573841224237056 |
---|---|
author | Groselj, Ales Bosnjak, Masa Krzan, Mojca Kosjek, Tina Bottyán, Kriszta Plesnik, Helena Jamsek, Crt Cemazar, Maja Kis, Erika Sersa, Gregor |
author_facet | Groselj, Ales Bosnjak, Masa Krzan, Mojca Kosjek, Tina Bottyán, Kriszta Plesnik, Helena Jamsek, Crt Cemazar, Maja Kis, Erika Sersa, Gregor |
author_sort | Groselj, Ales |
collection | PubMed |
description | The plasma concentration profile of bleomycin in the distribution phase of patients younger than 65 years is needed to determine the suitable time interval for efficient application of electric pulses during electrochemotherapy. Additionally, bleomycin concentrations in the treated tumors for effective tumor response are not known. In this study, the pharmacokinetic profile of bleomycin in the distribution phase in 12 patients younger than 65 years was determined. In 17 patients, the intratumoral bleomycin concentration was determined before the application of electric pulses. In younger patients, the pharmacokinetics of intravenously injected bleomycin demonstrated a faster plasma clearance rate than that in patients older than 65 years. This outcome might indicate that the lowering of the standard bleomycin dose of 15,000 IU/m(2) with intravenous bleomycin injection for electrochemotherapy is not recommended in younger patients. Based on the plasma concentration data gathered, a time interval for electrochemotherapy of 5–15 min after bleomycin injection was determined. The median bleomycin concentration in tumors 8 min after bleomycin injection, at the time of electroporation, was 170 ng/g. Based on collected data, the reduction of the bleomycin dose is not recommended in younger patients; however, a shortened time interval for application of electric pulses in electrochemotherapy to 5–15 min after intravenous bleomycin injection should be considered. |
format | Online Article Text |
id | pubmed-8469090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84690902021-09-27 Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group Groselj, Ales Bosnjak, Masa Krzan, Mojca Kosjek, Tina Bottyán, Kriszta Plesnik, Helena Jamsek, Crt Cemazar, Maja Kis, Erika Sersa, Gregor Pharmaceutics Article The plasma concentration profile of bleomycin in the distribution phase of patients younger than 65 years is needed to determine the suitable time interval for efficient application of electric pulses during electrochemotherapy. Additionally, bleomycin concentrations in the treated tumors for effective tumor response are not known. In this study, the pharmacokinetic profile of bleomycin in the distribution phase in 12 patients younger than 65 years was determined. In 17 patients, the intratumoral bleomycin concentration was determined before the application of electric pulses. In younger patients, the pharmacokinetics of intravenously injected bleomycin demonstrated a faster plasma clearance rate than that in patients older than 65 years. This outcome might indicate that the lowering of the standard bleomycin dose of 15,000 IU/m(2) with intravenous bleomycin injection for electrochemotherapy is not recommended in younger patients. Based on the plasma concentration data gathered, a time interval for electrochemotherapy of 5–15 min after bleomycin injection was determined. The median bleomycin concentration in tumors 8 min after bleomycin injection, at the time of electroporation, was 170 ng/g. Based on collected data, the reduction of the bleomycin dose is not recommended in younger patients; however, a shortened time interval for application of electric pulses in electrochemotherapy to 5–15 min after intravenous bleomycin injection should be considered. MDPI 2021-08-24 /pmc/articles/PMC8469090/ /pubmed/34575400 http://dx.doi.org/10.3390/pharmaceutics13091324 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Groselj, Ales Bosnjak, Masa Krzan, Mojca Kosjek, Tina Bottyán, Kriszta Plesnik, Helena Jamsek, Crt Cemazar, Maja Kis, Erika Sersa, Gregor Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group |
title | Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group |
title_full | Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group |
title_fullStr | Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group |
title_full_unstemmed | Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group |
title_short | Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group |
title_sort | bleomycin concentration in patients’ plasma and tumors after electrochemotherapy. a study from inspect group |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469090/ https://www.ncbi.nlm.nih.gov/pubmed/34575400 http://dx.doi.org/10.3390/pharmaceutics13091324 |
work_keys_str_mv | AT groseljales bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup AT bosnjakmasa bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup AT krzanmojca bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup AT kosjektina bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup AT bottyankriszta bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup AT plesnikhelena bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup AT jamsekcrt bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup AT cemazarmaja bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup AT kiserika bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup AT sersagregor bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup |